Skip to content

Construction and clinical applicability of diagnosis model of tissue origin in metastatic neuroendocrine neoplasms based on AI analysis and fusion data

Construction and clinical applicability of diagnosis model of tissue origin in metastatic neuroendocrine neoplasms based on AI analysis and fusion data

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2000036663
Enrollment
Unknown
Registered
2020-08-24
Start date
2020-10-01
Completion date
Unknown
Last updated
2020-09-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

neuroendocrine neoplasm

Interventions

Gold Standard:The organizational origin of clinical data is the gold standard
model&#32
of&#32
origin&#32
in&#32
neuroendocrine&#32

Sponsors

Fudan University Shanghai Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Histologically confirmed metastatic neuroendocrine tumors. 2) Surgically resected specimens or puncture biopsy specimens can be obtained. 3) There are enough formalin paraffin-embedded tissue (FFPE) tissue specimens. 4) No second tumor in the past 5 years or in the same time. 5) Complete clinicopathological and follow-up information. 6) Obtain the informed consent of the patient according to local laws and regulations, or obtain approval to exempt the informed consent.

Exclusion criteria

Exclusion criteria: 1) No neutral buffered formalin was used for tissue fixation; 2) Insufficient or transitional fixation of specimens in neutral buffered formalin fixative; 3) Specimens with incomplete clinical information; 4) Any incorrect tissue that causes changes in tissue quality during fixation, sectioning, embedding or preservation; 5) The quality of DNA/RNA extraction did not meet the requirements of sequencing.

Design outcomes

Primary

MeasureTime frame
accuracy;

Countries

China

Contacts

Public ContactDan Huang

Fudan University Shanghai Cancer Center

Dianehuangfdcc@gmail.com+86 18017317109

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026